Applicationof Machine Learning and MechanisticModeling to PredictIntravenous Pharmacokinetic Profiles in Humans

Accurate prediction of new compounds’ pharmacokinetic (PK) profile in humans is crucial for drug discovery. Traditional methods, including allometric scaling and mechanistic modeling, rely on parameters from <i>in vitro</i> or <i>in vivo</i> testing, which are labor-intensive and involve ethical concerns. This study leverages machine learning (ML) to overcome these limitations by developing data-driven models. We compiled a large data set of small molecules’ physicochemical and PK properties from public sources and digitized human plasma concentration–time profiles for approximately 800 compounds from the literature. We introduced a hybrid modeling framework that combines ML with physiologically based pharmacokinetic modeling and a hierarchical ML framework that employs two steps of learning to directly estimate PK profiles. Tested on 106 drugs, these frameworks demonstrated prediction accuracies within a 2-fold and 5-fold error for 40–60% and 80%–90% of compounds, respectively, in both AUC and <i>C</i><sub>max</sub>. Proposed approaches could enhance early molecular screening and design, advancing drug discovery capabilities.

Publication Details

Journal
Figshare
Published
2025-03-27
DOI
https://doi.org/10.1021/acs.jmedchem.5c00340.s002
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Applicationof Machine Learning and MechanisticModeling to PredictIntravenous Pharmacokinetic Profiles in Humans

Figshare
Computational Drug Discovery Methods
article

Applicationof Machine Learning and MechanisticModeling to PredictIntravenous Pharmacokinetic Profiles in Humans

article en

Abstract

Accurate prediction of new compounds’ pharmacokinetic (PK) profile in humans is crucial for drug discovery. Traditional methods, including allometric scaling and mechanistic modeling, rely on parameters from <i>in vitro</i> or <i>in vivo</i> testing, which are labor-intensive and involve ethical concerns. This study leverages machine learning (ML) to overcome these limitations by developing data-driven models. We compiled a large data set of small molecules’ physicochemical and PK properties from public sources and digitized human plasma concentration–time profiles for approximately 800 compounds from the literature. We introduced a hybrid modeling framework that combines ML with physiologically based pharmacokinetic modeling and a hierarchical ML framework that employs two steps of learning to directly estimate PK profiles. Tested on 106 drugs, these frameworks demonstrated prediction accuracies within a 2-fold and 5-fold error for 40–60% and 80%–90% of compounds, respectively, in both AUC and <i>C</i><sub>max</sub>. Proposed approaches could enhance early molecular screening and design, advancing drug discovery capabilities.

Figshare
Openalex Percentile: Top 60%
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.